BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-130@catalystbrief.girapphe.com
DTSTAMP:20261117T181600Z
LAST-MODIFIED:20261117T181600Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Readout: Merck Sharp & Dohme LLC — Sacituzumab tirumotecan [May 2
 027]
DESCRIPTION:Phase 3 primary completion: Sacituzumab Tirumotecan (MK-2870) V
 ersus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamou
 s Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic 
 Alterations (MK-2870-004).\nSource: https://clinicaltrials.gov/study/NCT06
 074588\nhttps://catalystbrief.girapphe.com/e/130?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/130?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
